Sort
16,300 grants matching “fatty liver disease”
Understanding and Addressing Cancer Health Disparities in Louisiana
$946,797Augusto C Ochoa · Lsu Health Sciences Center · P20 · FY2019 · CA
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis
$945,785Daniel J Lerner · Senseion Therapeutics, Inc. · R44 · FY2021 · DK
Metabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease Progression
$940,683M. Celeste Simon · University Of Pennsylvania · R35 · FY2022 · CA
COVID Effects on Experimental Alcohol-Associated Liver Disease and the Impact of Novel Nutritional Interventions
$939,000Craig J McClain · University Of Louisville · P20 · FY2022 · GM
Metabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease Progression
$931,087M. Celeste Simon · University Of Pennsylvania · R35 · FY2019 · CA
Early Life Social, Environmental, and Nutritional Determinants of Disease (ELSEND)
$930,613Michael I Goran · Children'S Hospital Of Los Angeles · P50 · FY2021 · MD
Molecular mechanisms of MASHNASH-related hepatocellular carcinoma
$930,599Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$929,121Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2021 · AA
Molecular Basis of Obesity and Obesity-induced Metabolic Diseases
$923,639Haiming Cao · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
Improving drug design to eliminate side effects: From computational to animal models
$923,348C. Denise Okafor · Pennsylvania State University, The · DP2 · FY2025 · GM
Noninvasive urinary monitoring of NASH by activity-based nanosensors
$923,177Eric Kai Huang · Glympse Bio, Inc. · R44 · FY2019 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease
$921,115Rohit Loomba · University Of California, San Diego · U01 · FY2022 · DK
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
$918,831David W Crabb · Indiana University Indianapolis · U01 · FY2015 · AA
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$916,147Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Therapeutic targets in African-American youth with type 2 diabetes
$914,529Stephanie Therese Chung · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
$913,866Mary Christine Playdon · University Of Utah · U01 · FY2022 · CA
Aging Intervention Program
$912,434Rafael De Cabo · National Institute On Aging · ZIA · FY2025 · AG
NHGRI/DIR Genomics Core
$912,066Settara Chandrasekharappa · National Human Genome Research Institute · ZIC · FY2016 · HG
Investigator Development Core
$911,254Donna D Spruijt-Metz · Children'S Hospital Of Los Angeles · P50 · FY2021 · MD
Novel therapeutics for fatty liver disease and type-II diabetes
$909,785Dave Musso · Southeast Techinventures, Inc. · R44 · FY2014 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease
$908,208Jordan Scott Orange · Columbia University Health Sciences · U01 · FY2019 · DK
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
$907,536Mary Christine Playdon · University Of Utah · U01 · FY2024 · CA
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$907,297Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2020 · AA
"Validation of Novel CKD Biomarkers in CRIC"
$905,907Chi-Yuan Hsu · University Of California, San Francisco · U01 · FY2012 · DK
Early Life Social, Environmental, and Nutritional Determinants of Disease (ELSEND)
$905,292Michael I Goran · Children'S Hospital Of Los Angeles · P50 · FY2025 · MD